Use of the ANTICIPATE NASH risk score to stratify patients with compensated MASH cirrhosis: data from a phase 3, double-blinded, randomized clinical trial assessing the safety and efficacy of pegozafermin (ENLIGHTEN-cirrhosis)

pegozafermin (RG6881) - Roche

https://events-distribution.easl.eu/from.storage?image=X9WvFraREucXDOc3lNmAYKuHN3iV6x8MWLSOYhub-p4bwYzFzYgTJL1mOFQeOJmJ0

Juan G Abraldes1; Arun J. Sanyal2; Rohit Loomba3; Quentin M. Anstee4; Hank Mansbach5; Cynthia L. Hartsfield5; Jasmine Dowlat5; Laura Contreras5; Jennifer B Kang5; Shibao Feng5; Maya Margalit5

May 13, 2026